The role of the FKBP51–Hsp90 complex in Alzheimer’s disease: An emerging new drug target
2024
FKBP51 and Hsp90: New Targets for Alzheimer's Disease Treatment
publication
Evidence: moderate
Author Information
Author(s): Jeanne Xavier, Török Zsolt, Vigh László, Prodromou Chrisostomos
Primary Institution: University of Sussex
Hypothesis
FKBP51 is a major player that elicits tauopathy in response to amyloid-beta senile plaques that damage the brain.
Conclusion
The Hsp90–FKBP51 complex is emerging as a promising drug target for Alzheimer's disease.
Supporting Evidence
- LA1011 was identified as a potential therapeutic against Alzheimer’s disease (AD).
- The molecular target of LA1011 was identified as the C-terminal domain of Hsp90.
- LA1011 disrupts the Hsp90–FKBP51 complex and downregulates tau hyperphosphorylation.
- The Hsp90–FKBP51 complex is a target for small-molecule therapies against AD.
Takeaway
As we get older, our brain's ability to keep proteins healthy declines, which can lead to Alzheimer's disease. A protein called FKBP51 may make this problem worse, but a new drug called LA1011 could help fix it.
Digital Object Identifier (DOI)
Want to read the original?
Access the complete publication on the publisher's website